

## Report from Extraordinary General Meeting in XVIVO Perfusion

The Extraordinary General Meeting in Xvivo Perfusion AB (publ) held on October 14, 2020 resolved to elect Lars Henriksson and Lena Höglund as new members of the Board of Directors. As previously communicated, the company's CEO Dag Andersson will resign as member of the Board in connection with the election of the new members. Consequently, the Board of Directors will consist of Gösta Johannesson (Chairman), Lars Henriksson, Lena Höglund, Yvonne Mårtensson, Folke Nilsson and Camilla Öberg.

The Meeting also resolved that each new board member shall receive an annual remuneration of SEK 175,000, i.e. adjusted for their terms.

Gothenburg, October 14, 2020  
Xvivo Perfusion AB (publ)

**For further information please contact:**

---

Dag Andersson, CEO, +46 76 643 30 31, e-post: [dag.andersson@xvivoperfusion.com](mailto:dag.andersson@xvivoperfusion.com)  
Christoffer Rosenblad, CFO, +46 73 519 21 59 e-post: [christoffer.rosenblad@xvivoperfusion.com](mailto:christoffer.rosenblad@xvivoperfusion.com)

**About Us**

---

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden, one office in Groningen, the Netherlands and one office in Denver, USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website [www.xvivoperfusion.com](http://www.xvivoperfusion.com).

**Attachments**

---

[Report from Extraordinary General Meeting in XVIVO Perfusion](#)